SAN DIEGO--(BUSINESS WIRE)--$TNDM #diabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced ...
The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...
Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...
DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.
BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA.
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...
DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback